Skip to main content
SICHUAN HEBANG BIOTECHNOLOGY CO.,LTD. logo

SICHUAN HEBANG BIOTECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603077 ISIN · CNE100001JM9 LEI · 30030072W72E4N589G74 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,743 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603077

About SICHUAN HEBANG BIOTECHNOLOGY CO.,LTD.

https://www.hebang.cn/

Sichuan Hebang Biotechnology Co., Ltd. specializes in the manufacturing and distribution of chemical products, agrochemicals, and advanced materials. The company leverages extensive salt and phosphate mineral resources to produce a diverse portfolio, including soda ash and ammonium chloride for industrial and agricultural applications. A significant portion of its operations is dedicated to the production of glyphosate, a broad-spectrum herbicide, and methionine, an essential amino acid for animal nutrition. Additionally, the company has expanded into the new energy sector, producing high-performance glass products such as float glass and photovoltaic glass. By integrating resource extraction with downstream chemical processing, the company maintains a vertically integrated supply chain, serving global markets in the chemical, agricultural, and renewable energy sectors.

Recent filings

Filing Released Lang Actions
和邦生物2026年第二次临时股东会法律意见书
Regulatory Filings Classification · 75% confidence The document is a legal opinion letter (“法律意见书”) from a law firm on the procedural legality of an extraordinary shareholders meeting and its voting results. It is not the meeting notice/proxy materials, nor a report such as an annual or interim financial statement, nor an earnings release. It contains legal opinions rather than substantive financial data. This type of legal opinion on a shareholders meeting does not match any specific category except the general “Regulatory Filings” fallback for miscellaneous compliance documents. Therefore, it is classified as RNS.
2026-05-29 Chinese
和邦生物关于第四期员工持股计划非交易过户完成的公告
Transaction in Own Shares Classification · 85% confidence The document is an official announcement from Sichuan Hebang Bio-tech regarding the non-trading transfer of 339,148,763 repurchased A-shares into the company’s fourth employee shareholding plan at a fixed price. It details the transfer date, price, share count, and plan terms. This is not a general report or prospectus but a corporate action involving the transfer of treasury shares. Accordingly, it falls under Transaction in Own Shares (POS).
2026-05-27 Chinese
和邦生物关于召开2026年第二次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a notice (“关于召开2026年第二次临时股东会的通知”) convening an extraordinary shareholders’ meeting, detailing meeting date, agenda, voting procedures, and proxy authorization form. It is not the meeting minutes or results, nor a financial report, but rather proxy solicitation/information materials to shareholders ahead of a vote. This corresponds to the Proxy Solicitation & Information Statement category (PSI).
2026-05-13 Chinese
和邦生物第七届董事会第一次会议决议公告
Board/Management Information Classification · 93% confidence The document is a board meeting resolution announcement (“董事会第一次会议决议公告”) detailing elections and appointments of the chairman, audit committee members, strategic committee members, general manager, CFO, board secretary, and securities affairs representative. It announces changes in board composition and key management roles. This matches the “Board/Management Information” category (Code: MANG).
2026-05-11 Chinese
和邦生物2025年年度股东会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 86% confidence The document is a legal opinion (“法律意见书”) issued by a law firm on the convening, procedures, eligibility and detailed vote outcomes of the company’s 2025 Annual General Meeting. It primarily reports the formal voting results on each agenda item. This aligns with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official shareholder vote results at general meetings.
2026-05-11 Chinese
首创证券股份有限公司关于和邦生物2024年度向不特定对象发行可转债之保荐总结报告书
Capital/Financing Update Classification · 88% confidence The document is a detailed “保荐总结报告书” issued by the sponsor (首创证券) summarizing its due diligence and continuous supervision duties for Sichuan Hebang’s 2024 convertible bond issuance. It is not an annual or interim financial report, earnings release, voting or board change notice, or dividend/ESG disclosure, but rather a full financing update surrounding the issuance of convertible bonds (a debt/equity hybrid fundraising activity). Under our taxonomy, this falls squarely under “Capital/Financing Update” (CAP).
2026-04-20 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.